Influenza, SARS-CoV-2 and RSV activity in EU/EEA Member States continue to decrease or remain stable at low levels. Cases, including severe infections, can still occur and it therefore remains essential to continue testing patients presenting with severe acute respiratory symptoms in order to guide treatment and inform epidemiological assessments.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 28 April - 4 May 2024 and includes updates on cholera, MERS-CoV, SARS-CoV-2, an overview of respiratory virus epidemiology in the EU/EEA, highly pathogenic avian influenza A(H5N1) in cattle and a related human case, Crimean-Congo haemorrhagic fever, and Lassa fever.
The European Centre for Disease Prevention and Control (ECDC) has published its latest Annual Epidemiological Reports shedding light on the state of sexually transmitted infections (STIs) in the European Union/European Economic Area (EU/EEA).
For 2022, 216 508 confirmed cases of chlamydia infection were reported in 27 EU/EEA countries, with a crude notification rate of 88 cases per 100 000 population.
Lymphogranuloma venereum (LGV) is a systemic sexually transmitted infection (STI) caused by Chlamydia trachomatis serovars L1, L2, or L3. In 2021, 1 124 cases of LGV were reported by 23 EU/EEA Member States.
For 2021, 27 EU/EEA Member States reported 184 542 confirmed cases of chlamydia infection. The crude notification rate was 74 cases per 100 000 population.
In a series of reports released by ECDC, a concerning rise in sexually transmitted infections (STIs) across Europe has been revealed indicating troubling trends and significant public health implications.